

## **Amendment to Program Information**

**Credit Suisse International**

## AMENDMENT TO PROGRAM INFORMATION

Type of Information: Amendment to Program Information

Date of Announcement: 24 March 2021

Issuer Name: Credit Suisse International

Name and Title of Representative: David Mathers  
Chief Executive Officer

Address of Head Office: One Cabot Square, London E14 4QJ, UK

Telephone: +44 (0)20 7888 8888

Contact Person: Attorney-in-Fact:  
Eiichi Kanda, Attorney-at-law  
Chihiro Ashizawa, Attorney-at-law  
Tomoki Goto, Attorney-at-law

Clifford Chance (Gaikokuho Kyodo Jigyo)  
Palace Building, 3rd floor  
1-1, Marunouchi 1-chome  
Chiyoda-ku, Tokyo 100-0005

Telephone: 81-3-6632-6600

Address of Website for Announcement: <https://www.jpx.co.jp/english/equities/products/tpbm/announcement/index.html>

Information on initial Program Information:

Date of Announcement: 20 August 2020

Scheduled Issuance Period: 21 August 2020 to 20 August 2021

Maximum Outstanding Issuance Amount: Unlimited

This amendment is filed to update the information included in the Program Information dated 20 August 2020 (as amended on 7 October 2020 and 27 January 2021). This constitutes an integral part of the Program Information dated 20 August 2020 (as amended on 7 October 2020 and 27 January 2021) and shall be read together with it.



## Credit Suisse International

### Debt Issuance Programme (Unlimited Program Size)

This Supplement (the "**Supplement**") is supplemental to, and should be read in conjunction with, (i) the Listing Supplement dated 2 October 2015 (the "**Listing Supplement**") in respect of the debt issuance programme established by Credit Suisse International ("**CSi**" or the "**Issuer**") on 10 August 2006 for the issuance of securities of CSi (the "**Securities**") (as supplemented from time to time), (ii) any other documents incorporated by reference therein and (iii) in relation to any particular Securities, the Pricing Supplement relating to those Securities. Capitalised terms used in this Supplement but not defined herein shall have the meanings ascribed to them in the Listing Supplement.

Supplement to Listing Supplement dated 24 March 2021

## DOCUMENTS INCORPORATED BY REFERENCE

The Listing Supplement and this Supplement should be read and construed in conjunction with the following document which shall be deemed to be incorporated in, and form part of, the Listing Supplement and the Supplement and supplement the section entitled "*Documents Incorporated by Reference*" of the Listing Supplement:

- (a) The CSi Registration Document approved by the UK Listing Authority (as may be supplemented and/or replaced from time to time) is incorporated by reference in respect of CSi. The latest CSi Registration Document and any supplements thereto are available at <https://www.credit-suisse.com/media/assets/investment-banking/docs/financial-regulatory/international/csi-registration.pdf>.
- (b) The annual and current reports, including interim financial information, and other relevant information of CSi, are incorporated by reference in respect of CSi and are available at <https://www.credit-suisse.com/ch/en/investment-banking/financial-regulatory/international.html>.

Copies of this Supplement will be available for inspection during normal business hours on any business day (except Saturdays, Sundays and legal holidays) at the offices of the Paying Agents. In addition, copies of the documents incorporated by reference in this Supplement (and any document incorporated by reference therein) will be available free of charge during normal business hours on any business day (except Saturdays, Sundays and legal holidays) at the offices of the Paying Agents and at the registered office of the Issuer.

## CREDIT SUISSE INTERNATIONAL

*The sections in the Listing Supplement entitled "Change" and "Legal and Arbitration Proceedings" shall be replaced with the information below.*

### Change

Apart from:

(1) the uncertainty relating to the impact of the ongoing global COVID-19 pandemic disclosed in the Listing Supplement (as supplemented) and the CSi Registration Document (as supplemented), including in (i) "Risk Factors—3. Market risk—3.1 The ongoing global COVID-19 pandemic has adversely affected, and may continue to adversely affect, CSi's business, operations and financial performance", (ii) the sections of the 2020 CSi H1 Interim Report (as defined in the CSi Registration Document) headed "Credit Suisse International at a glance—Operating environment" (on pages 10 to 13), "Performance" (on pages 14 to 18) and "Principal risks and uncertainties" (on pages 19 to 20), (iii) the sections of the Credit Suisse Financial Report 3Q20 (as defined in the CSi Registration Document) headed "I—Credit Suisse results—Operating environment" (on pages 4 to 6), "I—Credit Suisse results—Credit Suisse—Other information—COVID-19 and related regulatory measures" (on page 14) and "II—Treasury, risk, balance sheet and off-balance sheet—Risk management—Overview and risk-related developments—Key risk developments" (on page 60), and (iv) in the Credit Suisse Earnings Release 4Q20, the second paragraph of the section headed "2020 results" on page 4 and the section headed "COVID-19 pandemic and related regulatory measures" on page 10; and

(2) as more fully described in the exhibit (Credit Suisse Earnings Release 4Q20) to the Form 6-K Dated 18 February 2021, the impairment recognised relating to York Capital Management, the litigation provisions relating to mortgage-related matters, and the net loss that Credit Suisse reported in the fourth quarter of 2020,

there has been no significant change in the financial position of CSi since 30 June 2020.

Apart from the uncertainty relating to the impact of the ongoing global COVID-19 pandemic disclosed in the Listing Supplement (as supplemented) and the CSi Registration Document (as supplemented), including in (i) "Risk Factors—3. Market risk—3.1 The ongoing global COVID-19 pandemic has adversely affected, and may continue to adversely affect, CSi's business, operations and financial performance", (ii) the sections of the 2020 CSi H1 Interim Report (as defined in the CSi Registration Document) headed "Credit Suisse International at a glance—Operating environment" (on pages 10 to 13), "Performance" (on pages 14 to 18) and "Principal risks and uncertainties" (on pages 19 to 20), (iii) the sections of the Credit Suisse Financial Report 3Q20 (as defined in the CSi Registration Document) headed "I—Credit Suisse results—Operating environment" (on pages 4 to 6), "I—Credit Suisse results—Credit Suisse—Other information—COVID-19 and related regulatory measures" (on page 14) and "II—Treasury, risk, balance sheet and off-balance sheet—Risk management—Overview and risk-related developments—Key risk developments" (on page 60), and (iv) in the Credit Suisse Earnings Release 4Q20, the second paragraph of the section headed "2020 results" on page 4 and the section headed "COVID-19 pandemic and related regulatory measures" on page 10, there has been no material adverse change in the prospects of CSi since 31 December 2019.

Apart from the uncertainty relating to the impact of the ongoing global COVID-19 pandemic disclosed in the Listing Supplement (as supplemented) and the CSi Registration Document (as supplemented), including in (i) "Risk Factors—3. Market risk—3.1 The ongoing global COVID-19 pandemic has adversely affected, and may continue to adversely affect, CSi's business, operations and financial performance", (ii) the sections of the 2020 CSi H1 Interim Report (as defined in the CSi Registration Document) headed "Credit Suisse International at a glance—Operating environment" (on pages 10 to 13), "Performance" (on pages 14 to 18) and "Principal risks and uncertainties" (on pages 19 to 20), (iii) the sections of the Credit Suisse Financial Report 3Q20 (as defined in the CSi Registration Document) headed "I—Credit Suisse results—Operating environment" (on pages 4 to 6), "I—Credit Suisse results—Credit Suisse—Other information—COVID-19 and related regulatory measures" (on page 14) and "II—Treasury, risk, balance sheet and off-balance sheet—Risk management—Overview and risk-related developments—Key risk developments" (on page 60), and (iv) in the Credit Suisse Earnings Release 4Q20, the second paragraph

of the section headed "2020 results" on page 4 and the section headed "COVID-19 pandemic and related regulatory measures" on page 10, there has been no significant change in the financial performance of CSi since 30 June 2020 to the date of the CSi Registration Document.

### **Legal and Arbitration Proceedings**

During the period of 12 months ending on 8 March 2021, the date of the sixth supplement to the CSi Registration Document, there have been no governmental, legal or arbitration proceedings which may have, or have had in the recent past, significant effects on the financial position or profitability of the Issuer and the Issuer is not aware of any such proceedings being either pending or threatened, except as disclosed in the 2019 CSi Annual Report (as defined in the CSi Registration Document) under the heading "Contingent Liabilities and Other Commitments" (Note 40 to the consolidated financial statements of the Issuer) on pages 127 to 128, in the 2020 CSi H1 Interim Report (as defined in the CSi Registration Document) under the heading "Contingent Liabilities and Other Commitments" (Note 23 to the consolidated interim financial statements of the Issuer) on page 58, in the Form 6-K Dated 29 October 2020 under the heading "Litigation" (Note 33 to the condensed consolidated financial statements of Credit Suisse Group AG on pages 150 to 151 of the exhibit (Credit Suisse Financial Report 3Q20) to the Form 6-K Dated 29 October 2020), and in the Credit Suisse Earnings Release 4Q20 under the heading "Litigation" on page 5 of the exhibit (Credit Suisse Earnings Release 4Q20) to the Form 6-K Dated 18 February 2021.

Provision for litigation is disclosed in Note 29 to the consolidated financial statements on page 94 of the CSi 2019 Annual Report (as defined in the CSi Registration Document) and in Note 23 to the consolidated interim financial statements on page 58 of the 2020 CSi H1 Interim Report (as defined in the CSi Registration Document).